๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach

โœ Scribed by Stefano Bellentani; Riccardo Dalle Grave; Alessandro Suppini; Giulio Marchesini


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
130 KB
Volume
47
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

โœฆ Synopsis


Nonalcoholic fatty liver disease (NAFLD) is systematically associated with insulin resistance and the metabolic syndrome, where behavior therapy remains the primary treatment, simultaneously addressing all the clinical and biochemical defects. However, very few studies have tested the effectiveness of intensive behavior therapy in NAFLD, aimed at lifestyle modifications to produce stable weight loss by reduced calorie intake and increased physical activity. Searching the literature for studies testing weight loss and lifestyle modifications for the treatment of NAFLD, only 14 reports were traced where the entry assessment satisfied well-defined criteria. The final effectiveness was based on hard histological outcomes in 5 cases. All but 1 were pilot, uncontrolled studies or limited case series, and in general the details of treatment were scanty. In only 3 cases treatment was carried out along the guidelines of behavior treatment to reduce excess nutrition and increase exercise; in these cases, a remarkable effect on weight loss and an improvement in liver histology were reported. The principles of behavior therapy are presented in detail, to help physicians change their prescriptive attitude into a more empowerment-based approach. A brief section is also included on the practical aspects and public policies to be implemented at societal level to obtain the maximum effects in lifestyle changes. There is a need for multidisciplinary teams including dietitians, psychologists, and physical activity supervisors caring for patients with NAFLD. Alternatively, general practitioners and physicians working in gastrointestinal units should limit their intervention to engage patients with NAFLD before referral to specialized teams set up for the treatment of diabetes and obesity.


๐Ÿ“œ SIMILAR VOLUMES


Need for a three-focused approach to non
โœ Giovanni Musso; Roberto Gambino; Maurizio Cassader ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 296 KB

We read with interest the reviews by Ghouri et al. 1 and Martinez et al. 2 Ghouri et al. analyzed the association of nonalcoholic fatty liver disease (NAFLD) with cardiovascular disease (CVD) and concluded that although a diagnosis of NAFLD should prompt diabetes screening, it is insufficient for co

Hypouricemic therapy: A novel potential
โœ Cheng-Fu Xu; Chao-Hui Yu; Lei Xu; Xiao-Ying Sa; You-Ming Li ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 411 KB ๐Ÿ‘ 1 views

We read with great interest the practice guidelines for the diagnosis and management of autoimmune hepatitis recently issued by the American Association for the Study of Liver Diseases (AASLD). 1 In particular, we appreciate the new definition of biochemical remission, which now requires not only no

Nonalcoholic fatty liver in a developing
โœ Ajay Duseja; Balkrishan Sharma; Amit Kumar; Shweta Kapil; Ashim Das; Radha K. Dh ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 379 KB ๐Ÿ‘ 1 views

We read with great interest the article by Cavazza et al., 1 who demonstrated that an advanced histological stage was the only risk factor associated with the development of hepatocellular carcinoma (HCC) in patients with primary biliary cirrhosis (PBC) from two European centers. Similar results wer

Betaine for nonalcoholic fatty liver dis
โœ Manal F. Abdelmalek; Schuyler O. Sanderson; Paul Angulo; Consuelo Soldevila-Pico ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 227 KB ๐Ÿ‘ 2 views

Based on animal studies and pilot studies in humans, betaine, a methyl donor for the remethylation of homocysteine, may be a therapeutic agent for nonalcoholic steatohepatitis (NASH). We evaluated the safety and efficacy of betaine for patients with NASH and whether betaine positively modified facto